Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

• Status: Active, not recruiting
• Trial end date: 2022-03-01

Summary

The primary objectives of this study are:

Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most appropriate dose of lenzilumab for Phase 2.

Phase 2: To evaluate the incidence of neurologic events with sequenced therapy given at the recommended Phase 2 dose (RP2D) of lenzilumab in participants with relapsed or refractory large B-cell lymphoma.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Kite, A Gilead Company
• Collaborator: Humanigen, Inc.
• Treatments: Antibodies; Cyclophosphamide; Fludarabine; Fludarabine phosphate